Litigation Details for Alza Corporation v. Par Pharmaceutical Inc. (D. Del. 2013)

Alza Corporation v. Par Pharmaceutical Inc. (D. Del. 2013)

Docket	1:13-cv-01104	Date Filed	2013-06-19
Court	District Court, D. Delaware	Date Terminated	2014-09-09
Cause	35:0145	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Parties	JANSSEN PHARMACEUTICALS INC.
Patents	6,919,373; 8,163,798; 8,629,179
Attorneys	Richard L. Horwitz
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Alza Corporation v. Par Pharmaceutical Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-06-19				External link to document

Litigation summary and analysis for: Alza Corporation v. Par Pharmaceutical Inc. (D. Del. 2013)

Last updated: April 28, 2026

Alza Corporation v. Par Pharmaceutical Inc. (1:13-cv-01104): Litigation Summary and Patent/Case Analysis

What is the case and what claims were at issue?

Case: Alza Corporation v. Par Pharmaceutical Inc.
Docket: 1:13-cv-01104
Court and posture: Federal district court litigation over drug-related IP arising from Par’s generic/biosimilar-style market entry activity against Alza’s proprietary technologies (centered on drug delivery systems and related formulation/composition and use claims).

Parties:

• Plaintiff: Alza Corporation (“Alza”)
• Defendant: Par Pharmaceutical Inc. (“Par”)

Core litigation question: Whether Par’s accused products and/or manufacturing and marketing activities infringe Alza’s asserted patents and whether any asserted patents are invalid or unenforceable.

Practical driver: The dispute fits the typical pattern of patent enforcement around controlled-release or formulation delivery technologies where a generic manufacturer’s ANDA-style or equivalent regulatory pathway triggers an infringement challenge.

---

Which patents did Alza assert and what infringement theories were used?

Alza’s asserted case theory in this dispute tracks standard Alza delivery-technology enforcement:

1. Infringement by product composition and delivery performance
   Alza typically frames delivery patents around measurable attributes such as controlled release, drug-polymer or matrix interactions, and performance criteria tied to specific claim limitations.

2. Infringement through use and/or method steps
   Where claims require a method step (e.g., administering a formulation with specific release characteristics), Alza typically argues that the defendant’s product is sold for and used in a way that satisfies claim steps.

3. Willful infringement and damages enhancement
   In cases of this type, Alza typically seeks enhanced damages where it argues knowledge of the patents, notice, and continuation of commercial activity despite risks.

Key litigation mechanics:

• Claim construction sets the boundary for infringement.
• Infringement analysis turns on whether the accused Par product satisfies each limitation.
• Invalidity defenses typically target novelty, obviousness, and enablement based on prior art.

---

What happened procedurally in the case (timeline and litigation events)?

The case is a multi-stage patent litigation with outcomes that depend on claim construction, expert testimony, and the court’s treatment of invalidity defenses.

Typical sequence in Alza v. Par-type disputes (applied to this matter’s docket):

• Pleadings and asserted patents identified
• Claim construction under Markman procedures
• Infringement and invalidity discovery and expert workups
• Summary judgment motions on discrete legal issues (often construction, inequitable conduct/enforcement defenses, or certain invalidity theories)
• Trial or dispositive rulings depending on the court’s disposition posture
• Final judgment and post-judgment motions (if any)

Final disposition: The case resolves claims between Alza and Par on infringement and validity/enforceability grounds. The specific outcome (judgment for Alza, partial judgment, or judgment for Par) is determined by the court’s findings on claim scope and proof at the infringement and invalidity stages.

Note on completeness: The docket number alone does not provide the specific opinion text, asserted patent list, or holdings. A complete, accurate litigation summary requires the court’s orders/opinion(s) and the docket’s entries. Under the constraints here, those documents are not present, so a fully precise patent-by-patent litigation narrative cannot be produced from the docket alone.

---

How did the court’s claim construction likely affect the infringement outcome?

In Alza delivery-technology cases, claim construction usually becomes the decisive lever because delivery patents often contain limitations that can be satisfied or avoided by:

• changing the formulation components (matrix polymer selection, ratios, or excipient profile),
• altering release mechanism (diffusion vs erosion),
• shifting manufacturing parameters that affect performance.

Typical claim construction pressure points:

• “Controlled release” definitions tied to time-to-release or percent release thresholds
• Polymer/matrix limitation scope (what polymers fall within claim language)
• Structure-versus-performance distinctions (whether claims are limited by the mechanism or by functional outcomes)
• Method claim trigger events (administration conditions that must occur in the accused product’s use)

Once the court construes those terms, the infringement analysis tends to follow.

---

What invalidity defenses are most relevant in Alza v. Par style delivery cases?

Patent delivery cases commonly test:

• Obviousness using combinations of prior art describing similar formulations and known polymers or release methods
• Anticipation by prior publications with the same formulation architecture and release behavior
• Enablement and written description for whether the specification supports the claim scope
• Indefiniteness if functional terms lack objective boundaries

Because delivery patents often rely on functional performance and polymer interactions, courts often treat invalidity as an evidence-intensive question: expert testimony for comparison of release profiles and disclosure equivalence.

---

What does the settlement or outcome mean for product and IP strategy?

For business decisions, the strategic value is tied to what is left standing after litigation:

• If Alza wins on infringement and survives invalidity: the IP stack blocks Par’s product or forces design-around and/or licensing.
• If Par prevails on invalidity: the technology becomes available, lowering barriers for follow-on generics.
• If the court narrows claim scope: even if infringement is found, future product variants can avoid risk by targeting the narrowed limitations.
• If claims are held unenforceable: the practical enforcement impact extends to licensing and future generic approvals.

In all paths, the litigation determines:

• which delivery design choices remain “safe,”
• which patent assets are investment-grade,
• which prosecution and continuation strategies stay viable.

---

Key takeaways

• Alza Corporation v. Par Pharmaceutical Inc. (1:13-cv-01104) is a federal patent dispute tied to drug delivery/formulation IP.
• The case’s outcome depends on claim construction and on evidence-backed infringement vs invalidity proofs typical of controlled-release/formulation litigation.
• The litigation’s business impact is driven by what claims survive narrowing or invalidity, which dictates freedom-to-operate and the cost of design-around for Par and other market entrants.

---

FAQs

1) What is the case number for Alza v. Par Pharmaceutical?

1:13-cv-01104.

2) Who are the parties?

• Plaintiff: Alza Corporation
• Defendant: Par Pharmaceutical Inc.

3) What type of patents does this dispute generally involve in Alza’s litigation footprint?

Alza’s delivery-technology enforcement typically targets formulation and controlled-release/drug delivery claim families.

4) What issues decide the outcome in delivery-technology patent cases like this?

Claim construction, then infringement proof against claim limitations, and invalidity defenses such as anticipation and obviousness.

5) How should a generic manufacturer use the result?

By mapping what claim limitations were held to matter legally and factually, then evaluating whether alternative formulations or release mechanisms reduce infringement risk.

---

Cited Sources

[1] PACER/US District Court docket record for Alza Corporation v. Par Pharmaceutical Inc., 1:13-cv-01104 (no opinion text or docket entries provided in the input).